GlassScriptPhysician profile
Beth A Jones
NPI 1215508569
$4,725.77
in general payments reported to CMS, 2019-2025
32 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $1,078 · 2023: $1,145 · 2024: $1,162 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.48 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,502.98 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $297.57 | 2022 | |
| Emd Serono, INC. | $267.34 | 2023-2025 | Mavenclad, Mavenclad |
| Axsome Therapeutics, INC. | $257.14 | 2025 | Symbravo |
| Pfizer INC. | $248.42 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $207.76 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $186.64 | 2024 | |
| Lundbeck LLC | $183.48 | 2022-2025 | Vyepti |
| Sk Life Science, INC. | $162.50 | 2022-2023 | Xcopri |
| Acadia Pharmaceuticals INC | $153.95 | 2024 | Nuplazid |
| Eisai INC. | $151.55 | 2022-2024 | |
| Ucb, INC. | $133.91 | 2022-2024 | Rystiggo |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $94.25 | 2022-2024 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $86.88 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $83.13 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $74.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $73.71 | 2022 | |
| Lilly USA, LLC | $63.45 | 2022-2024 | Kisunla, Amyvid |
| Medline Industries LP | $63.33 | 2024 | Medline |
| Argenx US, INC. | $54.17 | 2023-2025 | Vyvgart |
| Tg Therapeutics, INC. | $36.87 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.91 | 2025 | Hyqvia |
| Biogen, INC. | $29.97 | 2025 | Vumerity, Tysabri, Avonex |
| Otsuka America Pharmaceutical, INC. | $25.77 | 2023 | Rexulti |
| Cala Health, INC. | $22.93 | 2025 | Cala Kiq |
| Genentech USA, INC. | $21.57 | 2024 | Ocrevus |
| Acorda Therapeutics, INC | $19.97 | 2023 | Inbrija, Ampyra |
| Horizon Therapeutics Plc | $18.74 | 2022 | |
| Csl Behring | $18.22 | 2024 | Hizentra |
| Upsher-Smith Laboratories LLC | $14.62 | 2021 | |
| Livanova USA, INC. | $14.52 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.